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Abstract | Sports-related concussions and repetitive subconcussive exposure are increasingly recognized
as potential dangers to paediatric populations, but much remains unknown about the short-term and longterm consequences of these events, including potential cognitive impairment and risk of later-life dementia.
This Expert Consensus Document is the result of a 1‑day meeting convened by Safe Kids Worldwide, the
Alzheimer’s Drug Discovery Foundation, and the Andrews Institute for Orthopaedics and Sports Medicine.
The goal is to highlight knowledge gaps and areas of critically needed research in the areas of concussion
science, dementia, genetics, diagnostic and prognostic biomarkers, neuroimaging, sports injury surveillance,
and information sharing. For each of these areas, we propose clear and achievable paths to improve the
understanding, treatment and prevention of youth sports-related concussions.
Carman, A. J. et al. Nat. Rev. Neurol. advance online publication 17 March 2015; doi:10.1038/nrneurol.2015.30

Introduction

In 2009, around 250,000 nonfatal traumatic brain injuries
(TBIs) were recorded among individuals aged <19 years
in the USA. 1 The Centers for Disease Control and
Prevention estimate that young people aged 5–18 years
sustain 65% of all sports-related concussions.2 Despite
recent advances in diagnostic brain imaging and in our
understanding of the physics of concussion, long-term
cognitive outcomes remain poorly understood. As the
physical, cognitive and emotional consequences of concussion gain wider public attention, our incomplete
knowledge of how to prevent, diagnose and treat such
injuries endangers the health of our children in general
and the health of their brains in particular.
This Expert Consensus Document is the result of a
1‑day meeting of experts in the fields of paediatric and
adult TBI, Alzheimer disease (AD) research, genetics,
epidemiology, bioethics and sports medicine (Box 1),
which was convened in November 2013 by Safe Kids
Worldwide, the Alzheimer’s Drug Discovery Foundation
and the Andrews Institute for Orthopaedics and Sports
Medicine. Our primary goal is to highlight critical gaps
in our knowledge of child and adolescent concussion.
We emphasize areas where research is needed, such as
Competing interests
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development of diagnostic and predictive biomarkers,
elucidation of genetic risk factors, and prediction of
short-term and long-term outcomes. In our conclusions, we suggest paths toward improving our understanding of the long-term consequences of sports-related
paediatric concussion.

Current state of knowledge
Concussive TBI in young people
The term ‘concussion’ is often used interchangeably with
the term ‘mild TBI’ (mTBI), a potentially misleading
practice considering the possible extent of brain damage
and potential for chronic neuropsychological dysfunction following concussion. We should stress, however,
that most concussions resolve without sequelae. The
American Congress of Rehabilitative Medicine defines
mTBI as a Glasgow Coma Scale3 score of 13–15, with
loss of consciousness for <30 min and post-traumatic
amnesia lasting <24 h.4
Concussion describes a heterogeneous mixture
of injury phenotypes that depends on many factors,
including the magnitude, location and direction of head
impact. Despite a lack of macroscopic structural findings, concussive brain injury involves primary neur
onal injury caused by linear and rotational shear forces
that disrupt axonal and membrane function (diffuse
axonal injury, 5 ionic flux and glutamate excitotoxi
city), followed by secondary pathophysiological effects
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Box 1 | Safe Sports Think Tank
This Expert Consensus Document is the result of ‘Safe Sports Think Tank:
Exploring the relationship between childhood sports-related concussions and longterm cognitive outcomes’, a 1‑day meeting of US‑based experts in the fields of
paediatric and adult traumatic brain injury, Alzheimer disease research, genetics,
epidemiology, bioethics and sports medicine.

Participants
■■ Robert Cantu, Boston University School of Medicine, Boston, MA
■■ Aaron J. Carman, Alzheimer’s Drug Discovery Foundation, New York, NY
■■ R. Dawn Comstock, University of Colorado at Denver, Aurora, CO
■■ Penny A. Dacks, Alzheimer’s Drug Discovery Foundation, New York, NY
■■ Steven T. DeKosky, University of Virginia School of Medicine, Charlottesville, VA
■■ Rennie Ferguson, Safe Kids Worldwide, Inc., Washington, DC
■■ Howard M. Fillit, Alzheimer’s Drug Discovery Foundation, New York, NY
■■ Sam Gandy, Icahn School of Medicine at Mount Sinai, New York, NY
■■ James Gilbert, Metro Orthopedics & Sports Therapy, Silver Spring, MD
■■ Chad Gilliland, Andrews Institute for Orthopaedics and Sports Medicine, Gulf
Breeze, FL
■■ Gerard Gioia, George Washington School of Medicine, Rockville, MD
■■ Christopher Giza, Univeristy of California, Los Angeles, CA
■■ Michael Greicius, Stanford Center on Longevity, Stanford, CA
■■ Brian Hainline, National Collegiate Athletic Association, Indianapolis, IN
■■ Ronald L. Hayes, Banyan Biomarkers, San Diego, CA
■■ James Hendrix, Alzheimer’s Association, Chicago, IL
■■ Barry Jordan, Burke Rehabilitation Hospital, White Plains, NY
■■ James Kovach, CrowdOptic, Inc., San Francisco, CA
■■ Rachel F. Lane, Alzheimer’s Drug Discovery Foundation, New York, NY
■■ Rebekah Mannix, Children’s Hospital, Harvard Medical School, Boston, MA
■■ Thomas Murray, The Hastings Center, Garrison, NY
■■ Tad Seifert, Norton Healthcare, University of Kentucky, Louisville, KY
■■ Diana W. Shineman, Alzheimer’s Drug Discovery Foundation, New York, NY
■■ Eric Warren, Novant Health Sports Medicine, Waxhaw, NC
■■ Elisabeth Wilde, Baylor College of Medicine, Houston, TX
■■ Huntington Willard, Marine Biological Laboratory, Woods Hole, MA

including mitochondrial oxidative stress, disruption of
cerebral blood flow, compromised blood–brain barrier
(BBB) integrity, synaptic dysfunction, and neuroinflammation.6,7 Lasting neuropsychological post-concussion
symptoms (post-concussion syndrome) comprise
mood disorders (for example, depression), difficulty
concentrating, and memory problems (Box 2).8
Susceptibility and resilience of young brains
Both physical and physiological components of concussive injury can damage the developing brain, putting
youths engaged in impact sports at particular risk. The
necks and torsos of young athletes are weaker than
those of older individuals and, consequently, less force
is required to cause brain injury. The developing brain
might also be particularly vulnerable to axonal damage
caused by the shearing forces of head trauma, which, in
youth American football, can exceed linear acceleration
forces of 100 g.9 However, the average forces sustained
in youth sports will generally be smaller than at higher
levels of sport.
Proper synaptic development is critical to cognitive and
behavioural health.10–15 Processes such as neurogenesis,
competitive synaptic elimination (‘pruning’), myelin
ation, and axonal and dendritic arborization continue
from prenatal development throughout the lifespan.14 The
frontal and temporal lobes are the last areas to mature,

and humans experience pruning in these regions into
their early 20s,16 so damage to these still-developing areas
may have pathophysiological effects on the brain that
increase the potential for n
 europsychological p
 roblems
later in life.17
Axonal myelination continues through adolescence
into the early 20s, and is susceptible to disruption by
injury.10,18–22 Early results from the Professional Fighters
Brain Health Study, a 5‑year longitudinal study of boxers
and mixed martial arts fighters, who experienced repetitive subconcussive injuries as well as concussions, indicate that earlier age of first exposure to competitive
boxing correlates with greater loss of caudate volume and
greater axonal damage in the frontal lobe.23,24
The young brain also has features that contribute to
its resilience. Increased neuroplasticity in this age group
has been shown to contribute to better outcomes after
focal injuries.25 In addition, developing animals display
a shorter window of glucose metabolic impairment in
response to repeat TBI than do adult animals.26
Overall, the developing brain shows both vulnerability
and resilience after TBI. These interwoven factors are
likely to account for differences in the effects of concussion and repeat mTBI on young versus adult brains. A
conservative approach to concussion risk and greater
efforts to investigate these developmental differences
should be given high priority.
Recovery
Most people—both young and old—recover fully from
concussions. In children, factors potentially influencing
recovery include age and history of concussions. 27,28
In one study, approximately 90% of young adult male
athletes experienced symptomatic recovery within
21 days.29 However, in an emergency department study
of patients aged 11–22 years (including all causes of
concussion, not just sports-related), 15% of the sample
still exhibited post-concussion symptoms, including
headache, dizziness, ‘mental fogginess’ and depression,
90 days after injury.30 Several studies suggest that high
school American football players are slower to recover
from concussion than are college31,32 and professional
players.33 No direct comparisons with adolescents below
high school age have yet been published, although a
recent study that included a pre-adolescent age group
(11–12 years) suggested that post-concussion recovery
duration may not exhibit a linear relationship with age,30
as adolescents in this sample took longer to recover than
did the pre-adolescent children. These findings, taken
together, imply a unique risk of lengthier recovery in the
male adolescent age group. Further studies of younger
children and females would add greatly to our ability
to assess and mitigate risk across the full paediatric and
adolescent age span.
Youths who sustained one or more concussions within
1 year prior to a new concussion reported more-prolonged
symptoms,30 suggesting a possible ‘window of vulnerability’, and placing previously injured youths at higher
risk of protracted recovery. Adolescents aged 11–18 years
were nearly 80% more likely to develop post-concussion

2 | ADVANCE ONLINE PUBLICATION

www.nature.com/nrneurol
© 2015 Macmillan Publishers Limited. All rights reserved

CONSENSUS STATEMENTS
syndrome after presenting in emergency rooms than
were children aged 5–10 years; similarly, presentation
with headache doubled the risk of post-concussion syndrome in both children and adolescents.34 Among children treated in an emergency room after mTBI, those
aged >6 years reported higher rates of persistent symptoms 3 months post injury than did those aged <6 years.35
Of course, the ability to acquire accurate information
about concussion symptoms in children <6 years of age
may be limited by a lack of self-awareness of symptoms
and the necessary verbal skills to effectively communicate
those symptoms. Also, direct comparison of injury severity is not possible from these reports; in fact, the physical heterogeneity of various injuries, taken together with
the individual’s innate capacity to recover from concussion, makes such comparisons highly challenging. ‘Smart
helmets’ are being used in some speciality research centres
to standardize the physical force and angular acceleration that accompanies head hits, and the utility of these
helmets to measure and predict impacts that may result in
concussion is c urrently under investigation.36,37
Young people recovering from concussion can experience important challenges, including altered social and
academic development,38–40 lower scores on general intelligence tests, and decreased school performance (measured by grade-point average).39 Lower levels of parental
education and child academic achievement both correlate with poorer concussion recovery.41 Personality
traits also play a part; for example, pre-injury anxiety
is a risk factor for prolonged recovery periods after
sports-related concussion.42
Young athletes of both sexes are at risk of concussion, but girls report higher concussion rates than
boys, particularly in high school and college soccer,
basketball, and baseball or softball.28,43–45 The factors
that account for these differences remain uncertain, but
might include quality of protective gear, recognition and
reporting of concussion symptoms, and neck length
and neck muscle strength. 46 Differences in recovery
trajectories between males and females are also poorly
understood. However, one recent study suggested that
progesterone levels in females influence post-concussion
recovery.47 Hormonal changes during puberty that contribute to migraine headaches might also contribute to
sex differences in concussion recovery. Migraine headaches are up to fourfold more common in females than
in males after puberty,48,49 and some evidence suggests
that migraineurs recover more slowly after concussion.50,51 Research is warranted to further delineate sex
differences in c oncussion risk and recovery.
In general, adult concussive brain injury is much
better understood than its counterpart in children and
adolescents. Several points are important to note. First,
concussion has multiple, non-harmonized definitions.
Second, concussion diagnosis is an imperfect art. Last, in
the absence of rapid and inexpensive objective diagnostic
measures, concussion remains a clinical diagnosis that
is subject to variability—including different thresholds
for diagnosis across various subspecialities and across
individual physicians, neuropsychologists and athletic

Box 2 | Characteristics of concussion
Clinical classification
■■ Glasgow Coma Scale score 13–15
■■ Loss of consciousness <30 min
■■ Post-traumatic amnesia <24 h
Primary brain injuries
■■ Lack of gross structural changes (that is, haemorrhage,
contusion)
■■ Axonal function disrupted by linear and rotational sheer
forces
■■ Glutamate release and ionic flux
Potential secondary brain injuries
■■ Disrupted blood–brain barrier function
■■ Neuroinflammation
■■ Mitochondrial oxidative stress
■■ Disrupted cerebral blood flow
■■ Disrupted connectivity networks
Potential neuropsychological outcomes
■■ Executive dysfunction
■■ Attentional dysfunction
■■ Memory problems
■■ Slowed processing speed
■■ Altered mood
■■ Depression

trainers—and under-reporting by coaches, parents and
young athletes. Without validated diagnostics, concussion will remain a nebulous and under-reported
entity, and the accuracy of incidence estimates will
continue to be tainted by the differential application of
inexact criteria.
Subconcussive blows
Repetitive subconcussive trauma can result in structural
and functional brain changes.52 White matter abnormalities detected by diffusion tensor imaging (DTI) have
been reported in professional soccer players even in the
absence of any obvious history of concussions. Compared
with swimmers, male professional soccer players showed
DTI signal changes suggestive of decreased white matter
integrity in several brain regions, which might indicate
loss of axonal myelination, similar to changes seen in
individuals with mTBI.53 Collegiate ice hockey players
exhibited similar white matter changes over the course of
a season.54–57 In addition, repetitive subconcussive head
impacts in collegiate American football players have
been linked, in a dose-dependent manner, to deficits in
BBB integrity, potential loss of white matter integrity, and
cognitive dysfunction.58
These findings probably reflect some level of risk
for youths who sustain repetitive subconcussive head
impacts, although little research has been devoted speci
fically to this topic. A metric to track head impacts—that
is, a ‘hit count’—has been proposed,59 and could serve
as one factor to determine cumulative risk exposure.
One challenge of this approach is to accurately define
the parameters of a ‘hit’, but improved biosensors show
some promise in this regard. Similar to a ‘pitch count’
in baseball, this concept has also recently been proposed for boxers.24 No evidence is currently available
to show a causal link between repetitive subconcussive
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head impacts in youth and dementia later in life, and
such metrics could prove invaluable if validated by
future studies correlating head impacts with subsequent
neuropsychological dysfunction.
Filling the gaps—concussion risk and recovery
■■ Identify the drivers of age differences in sports-related
concussion risk. Does age influence the concussion
recovery trajectory?
■■ Determine drivers of sex differences in sportsrelated concussion risk. Does sex influence the concussion recovery trajectory? Are the effects of sex
age-dependent?
■■ Establish how cumulative subconcussive head blows
influence short-term and long-term n
 europsychological
dysfunction

Neurodegeneration and cognitive impairment
CTE
In adults, TBI, including concussion,60–62 might increase
an individual’s risk of developing neurodegenerative
disease,63,64 including AD and chronic traumatic encephalopathy (CTE), a disease associated exclusively with
repetitive head trauma.65,66 TBI may also increase the
risk of developing Parkinson disease (PD),67 although
the relationship between mTBI and PD risk remains
uncertain.68 In paediatric populations, particularly young
athletes, the effects of single or repetitive concussions
on the risk of later-life neurodegeneration and dementia
are unknown.
CTE was first described symptomatically in the
late 1920s as ‘punch-drunk’ dementia in boxers,69 was
later described as ‘dementia pugilistica’,70 and was first
described pathologically in 1973.71 Since the identification of CTE in a former professional American football
player in 2005,72 and additional intensive pathological
studies, this condition has gained widespread public
attention, and has now been identified in brains of
former ice hockey, baseball, rugby and soccer players,73
wrestlers,74 and military veterans.75,76 The prevalence and
incidence of CTE in amateur and professional athletes
is still unknown, adding to difficulties in discussing its
epidemiology and population risks for athletes. Although
CTE is primarily considered to be a neurodegenerative
disease that sometimes results from a career of either
collegiate or professional contact sports, cases of CTE
have been reported in high school athletes.77 This finding
suggests that long sporting careers are not required for
CTE development, and that youth athletes represent an
at-risk population.
Emerging evidence suggests that clinical CTE symptoms can be grouped into two common presentations:
cognitive and mood–behavioural.78,79 Subjective memory
complaints such as anterograde amnesia are common,
as are mood disorders including anxiety or depression,79
and reduced executive function, which can result in disinhibition and impaired decision-making skills.80 These
clinical symptoms define disease severity.81
The neurodegenerative pathophysiology of CTE
is complex, and the neurological sequelae are poorly

understood. In severe cases, the cerebral cortex and
medial temporal lobes seem most profoundly affected,81,82
with pathology characterized by neurofibrillary tangles
composed of phosphorylated tau79 and, in some cases,
TAR DNA-binding protein 43 pathology.83 CTE is also
associated with marked atrophy, notably in the frontal
cortex and medial temporal lobe, as well as in the mammillary bodies, thalamus and hypothalamus.79 Confirmed
clinical diagnosis of CTE remains autopsy-based.84
CNI
Given the uncertainty over whether the tauopathy
described in CTE is causative of the clinical phenotype,
and the fact that most professional and collegiate athletes
do not develop CTE, it is vital to understand whether
early exposure to concussion is associated with other
forms of neurodegeneration and cognitive dysfunction,
including chronic neurocognitive impairment (CNI).
Important clinical distinctions exist between CTE and
CNI,28,51 some of which make direct comparisons difficult. CTE is an emerging clinical and pathological
condition that involves progressive deterioration of
neurological and cognitive function in multiple domains,
and is diagnosed primarily at autopsy. Conversely, the
CNI phenotype is not necessarily progressive, and is
characterized by functional decline from group averages or baseline functioning established before TBI.
CNI can be diagnosed clinically through neuropsychological testing. No causal link between CNI and head
trauma has yet been confirmed, but a dose-dependent
risk has consistently been found in professional athletes.28 In addition, almost half of the studies conducted
in amateur athletes have found an elevated risk of CNI.28
Whether similar risk associations are present in younger
populations remains to be determined.
One hypothesis is that CNI represents a prodromal—
but not inevitable—step toward CTE, analogous to the
relationship between mild cognitive impairment (MCI)
and AD. 85,86 Alternatively, CNI may represent static
impairment without degeneration. Our current lack of
understanding of the basic biological underpinnings of
CNI and CTE underscores the need for more research.
Increased knowledge of the biology of both conditions,
as well as early detection of CNI in athletes (in particular, youth athletes), may drive interventions to stem the
development of further cognitive impairment, and could
also aid validation of putative biomarkers. Assessment of
CNI via tau imaging may help determine the likelihood
of progression to CTE.
Filling the gaps—CTE and CNI
■■ Identify the molecular initiators and drivers of CTE
pathology. Are similar drivers present in youths with
concussion?
■■ Capture the incidence and prevalence of CTE in
former professional and amateur athletes
■■ Improve early detection of CNI in athletes. Can early
detection and intervention reduce the frequencies of
psychiatric disorders, cognitive decline and later-life
dementia?
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Genetics of concussion and dementia
The field of concussion genetics, especially in paediatric
populations, is still in its infancy. Although repetitive
head impacts seem necessary for the development of
CTE, other factors, including genetics, are likely to have
an important role, as most concussed athletes do not
develop CTE.87 The genetic risk factors for CTE probably overlap with those that influence susceptibility to
and recovery from concussion, and genetic risk factors
for AD are providing important clues to the identity of
these factors.
Apolipoprotein E
The ε4 allele of apolipoprotein E (APOE ε4), the most
important genetic risk factor for AD identified to date,88
critically affects the CNS injury response,89 in particular, amyloid‑β (Aβ) clearance from the brain. The three
alleles of APOE confer varying degrees of AD risk:
APOE ε2 reduces the risk, APOE ε3, the most common
allele, represents baseline risk with which other variants are compared, and APOE ε4 increases the risk.90,91
Studies suggest an interaction between APOE ε4 and sex,
such that APOE ε4-related risk of AD is more prominent in women than in men.92,93 The APOE genotype acts
synergistically with TBI in increasing the risk of AD,94
although its hypothesized risk association with CTE as
an outcome of repetitive mTBI requires more study.95
No consensus has yet been reached on the effects of
APOE isotype on the outcome of paediatric TBI, but data
from adults suggest that APOE ε4 negatively influences
concussion outcomes. Several studies indicate that possession of at least one APOE ε4 allele is associated with
poorer cognition and lasting neuropsychological impairment after concussion in professional American football
players,96 boxers95 and other adults,97–100 although other
studies found no such association.101,102 Some evidence
points to polymorphisms in both the APOE gene and
its promoter as contributory factors to concussion risk
in college athletes.103,104 Another study did not identify a role for APOE ε4 in concussion risk,105 although
this allele might increase the risk of dementia following midlife or late-life mTBI.106 Drawing conclusions
from these conflicting studies is difficult, owing to small
sample sizes and differing methodologies.
In children, little is known about the relationship
between APOE ε4 and neuropsychological outcomes after
concussion, and APOE ε4 testing is not routine in paediatric TBI studies. In 2012, Kurowski reviewed the few existing studies and combined the results of three studies107–109
that used the Glasgow Outcome Scale.110 In the combined sample (252 children), the risk of poor clinical
outcomes after 6–12 months was over twofold higher in
APOE ε4 carriers than in noncarriers (19% versus 9%).
However, these studies included a broad developmental
range of children with heterogeneous injuries, and did
not account for a possible interaction between age and
genotype. In addition, the interaction between APOE
and sex has not been studied in the context of concussion. Improved p
 rospective studies are warranted to
clarify these connections.

Incorporation of genetics into paediatric concussion
research is fraught with complicated challenges, including acquisition of parental consent and informed consent
for a child, perceived stigmatization of clinical study
participants, the actionability of the genetic knowledge
obtained, and potential concerns regarding insurability (particularly long-term care insurance). Studies of
adults who learn of their APOE ε4+ status demonstrate
that many are willing to make lifestyle modifications,
including increased exercise and improved medication
management,111 as well as increased purchases of health
and long-term care insurance.112,113
Education about new genetic knowledge and corresponding disease risk is essential, as demonstrated by the
substantial discordance between an individual’s personal
feelings about the implications of the acquired knowledge and the actual consequences of increased dementia risk.114 The effects of APOE genetic knowledge on
children, their families and decision-making processes
regarding participation in impact sports remain unclear.
The influence of APOE genotype on concussion risk and
recovery in this age group also needs further elucidation. If future studies find that, for any particular level of
impact, children with APOE ε4+ status are at greater risk
of concussion or poor recovery than are their APOE ε4–
peers, consideration should be given to genetic testing of
school-age athletes before participation in impact sports.
Careful studies of high school and younger athletes
are required to fully understand the nuances of genetic
influences. Future research into youth concussion
outcomes, including cognitive outcomes and risk of
dementia, should include APOE genotyping wherever
possible. New APOE studies should standardize research
methodologies and reporting measures, including the
collection of ‘common data elements’, to ensure valid
comparison across studies.110,115 The APOE genotype
is not necessarily a non-modifiable risk factor for concussion recovery: therapies being developed for AD
include drugs that modify the interaction between the
ApoE4 protein and Aβ, which might also be applicable
to paediatric concussion.116,117
Other genetic risk factors
The Val66Met polymorphism in the gene encoding
brain-derived neurotrophic factor has been linked to
better outcomes after mTBI,118 but worse outcomes after
focal penetrating brain injury.119 Polymorphisms in genes
involved in dopaminergic signalling may also help to
account for the wide range of TBI outcomes.120 In addition, the Rep1 polymorphism in the promoter region of
the α‑synuclein gene might increase the risk of PD after
head injury.121
To advance our understanding of concussion risk
and management, large, prospective, population-based
genome-wide association studies (GWAS) and wholegenome sequencing studies should be conducted to identify other genetic variants—possibly of low frequency or
low penetrance—that modify the risk of prolonged recovery, poor cognitive outcomes or dementia.122 Such studies
will require large-scale data sharing, and must address
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issues of ethics, privacy, and potential i mplications for
insurability and employability.
Filling the gaps—genetic risk factors
■■ Better define the effects of genetic differences on concussion risk and recovery trajectories, with specific
attention to potential correlations between genetic
differences and age and sex differences
■■ Explore the genetic contribution to TBI susceptibility
and risk of post-concussion syndrome
■■ Consider increasing the use of genotyping in p
 aediatric
concussion research, including clinical trials
■■ Improve comparability and validity of future paediatric concussion research by increasing sample sizes (for
example, through multisite studies) and standardizing
study methodologies

Future directions
Diagnostic and prognostic biomarkers
Despite progress in identifying possible cerebrospinal
fluid (CSF) and blood-based biomarkers that might be
applied to adult TBI management, no clinically validated
biomarkers are available for either the adult or the paedi
atric population. Paediatric concussions present with
even greater clinical variability than do adult concussions;
therefore, biomarkers have special potential for improving concussion diagnosis in children. Of note, most TBI
biomarkers have been studied in the context of moderate to severe TBI, leaving us with obvious gaps in our
knowledge of mTBI biomarkers, especially in children.
Biomarker development has been critical to the
advancement of AD therapeutics. CSF-based biomarkers are already being employed to identify at-risk
patients and to improve the design of both epidemiological studies and clinical trials.123 New PET radioligands,
such as amyloid-labelling agents (three of which are now
FDA-approved), can be used both diagnostically and
to improve neuropathology-based patient stratification
for clinical trials. Several tau imaging agents are also in
human trials, and their utility in tauopathies, including
CTE, is rapidly being established. As with fluid-based biomarkers, there are currently no neuroimaging biomarkers
sensitive or specific enough to diagnose concussion
or CTE in either adults or children. No TBI diagnostic or
therapeutic agents have yet been approved by the FDA,
and validation of concussion biomarkers could accelerate the development of such agents. Efforts must be
made, however, to ensure the cost-effectiveness and wide
availability of clinical biomarker testing. Also, given the
risks associated with lumbar puncture, ethical concerns
regarding sampling of CSF from concussed youths for
biomarker research should be addressed.
Fluid-based biomarkers
Promising findings in adult fluid-based biomarker
research must be explored in paediatric populations.
Putative concussion biomarkers have emerged sporadically in the scientific literature over the past few decades,
the most prominent being S100 calcium-b inding
protein B (S100B), a nonspecific marker of astrocyte

activation. The presence of S100B in serum may indicate
loss of BBB integrity. Elevated serum and CSF levels of
S100B have been observed in adult boxers after matches,
and correlate positively with the number and severity of
head impacts.124,125 Increased serum S100B levels have
also been observed in concussed professional ice hockey
players,126 with levels measured 1 h post-concussion predicting symptomatic recovery time. However, S100B
levels were also raised after controlled play where no
concussions occurred, indicating that this marker is not
injury-specific.126 Indeed, S100B serum levels are elevated
in adult trauma patients without head injury.127–129 Other
research suggests that initial post-concussion S100B levels
are poor predictors of recovery.130
As with all biomarkers, the role of S100B in TBI
management in children is even less clear,131 with some
arguing that this marker has little diagnostic or prognostic utility in paediatric populations.132 In a study of
children with TBI aged ≤15 years, those <5 years or
>9 years of age had higher serum levels of S100B than
did those aged 5–9 years.133 S100B may, therefore, be an
inadequate marker to distinguish between symptomatic
and asymptomatic children with concussion,133 and the
utility of S100B in diagnostics and outcome prognosis
is questionable.134–136
Neuron-specific enolase (NSE) is a marker of neuronal
injury, but its usefulness as a serum or CSF biomarker
remains uncertain.133–137 Elevated serum NSE levels have
been observed after head impacts in boxers,124 but were
also seen in ice hockey players after a match where no
concussions occurred. 126 Serum NSE levels failed to
predict recovery time after concussion,126 and might not
correlate with injury severity in children.133 In children
aged ≤15 years, serum NSE levels correlate inversely
with age.133 Once released into the blood, NSE has slow
elimination kinetics, making it difficult to distinguish
primary from secondary neuronal injuries on the basis
of NSE levels.138,139
Neurofilament light chain and glial fibrillary acidic
protein (GFAP) are CSF neuron-specific and glial-
specific damage markers, respectively, and are both
elevated in CSF in adult boxers after fights.125,137,140 Little
is known about either marker in the context of paediatric concussion, but a preliminary study in children and
young adults suggested that serum GFAP levels within
72 h after concussion correlate with symptom burden up
to 1 month post injury.141
The neuron-specific protein UCH‑L1 (ubiquitin
carboxyl-terminal hydrolase isozyme L1) was first linked
to neurodegenerative pathology through its involvement
in PD,142 and its presence in serum was later identified
as a biomarker for severe TBI. 143–145 Serum levels of
UCH‑L1 may have diagnostic utility in concussion,146 but
recent evidence suggests a lack of correlation between
elevated serum levels and subconcussive hits.147 The clinical utility of UCH‑L1 in paediatric populations warrants
further study.
Perhaps the most promising advances in adult fluidbased TBI biomarkers concern tau protein. Serum or
CSF tau levels are thought to indicate axonal damage, as
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tau normally resides in axons, where it stabilizes microtubules. Serum tau is proteolytically cleaved,148 and in
patients with AD, levels of cleaved tau in CSF might correlate with cognitive function.149 Tau levels in CSF and
blood are elevated in boxers after a match, and CSF tau
levels correlate with the quality and quantity of head
impacts.125,150 Recent evidence suggests that tau levels are
elevated in the blood of ice hockey players after concussion, and may be useful in predicting recovery time.126
Questions remain, however, with several studies reporting little or no value of serum cleaved tau for predicting
post-concussion syndrome or long-term outcomes.130,151
The potential of tau as a biomarker in children remains
unclear, with no studies conducted to date. In fact, the
reliability of serum tau as a biomarker has not yet been
established for any indication.
The likelihood is that no single biomarker will suffice
to diagnose paediatric concussion or predict outcomes.
In addition, few studies have examined the interactions
between genetic make-up and putative biomarkers. As
our understanding of the relationships of biomarkers
to injury severity and to each other increases, development of biomarker panels, perhaps incorporating
inflammatory and oxidative markers,152 should be considered. Future studies should attempt to further define
these relationships and establish the clinical value of
biomarker panels, factoring in commercial cost and
practical feasibility.
Recent advances in metabolomics, lipidomics and proteomics—in particular, the search for metabolomic and
lipidomic markers for AD—might inform future research
into biomarkers for concussion and subconcussive injuries. Several recent studies propose altered metabolite
and lipid profiles associated with MCI and AD.153–156
Data from animal models suggest that lipid and metabo
lite changes accompany both acute and chronic postconcussion periods, and could be useful for predicting
recovery trajectory,157,158 but these findings have yet to be
validated in humans. Expanding the biomarker search
beyond blood and CSF to saliva and urine 159 might
improve the ability to obtain measurements rapidly and
noninvasively, particularly from children. Sampling of
CSF from children, particularly when rapid assessment is
desirable, is largely impractical. Mondello et al. proposed
a set of useful criteria for evaluating TBI biomarkers that
should allow more-streamlined development and validation.137 Any validated biomarker panel must, inevitably,
be a component of a larger, multimodal diagnostic suite
that may include structural and functional imaging and
neuropsychological testing. When designing future biomarker studies, the potential for FDA approval should be
considered, in order to expedite approval for clinical use.
Filling the gaps—fluid-based biomarkers
■■ Clarify the diagnostic and prognostic utility of existing fluid-based biomarkers, and expand sampling
beyond CSF and blood
■■ Explore the utility of lipid, metabolite, oxidative and inflammatory biomarkers, with up-front
consideration of FDA-approval requirements

■■ Explore the feasibility of practical implementation of rapid biomarker assessment in paediatric
sports-related brain injuries
■■ Validate potential biomarkers for clinical diagnosis
and recovery prognosis, and correlate biomarkers
with cognitive outcomes
Neuroimaging biomarkers
Although concussion remains a clinical diagnosis, neuro
imaging techniques are improving our understanding
of the structural and functional consequences in adults.
Neuroimaging in paediatric populations may be limited
by several factors; for example, measurements of longitudinal changes after concussion are complicated by the
background of a dynamic, immature brain. No imaging
techniques have been validated as diagnostic tools for
concussion, and the correlation between imaging findings and clinically measurable cognitive or behavioural
functions is variable. Tools such as volumetric imaging,
DTI and functional MRI (fMRI)—in particular, arterial
spin labelling—are currently being explored.160,161
Fractional anisotropy (FA), as measured by DTI, allows
inference of the structural integrity of white matter tracts,
which are commonly disrupted after TBI. The clinical
implications of FA change remain controversial, as both
increased and decreased FA has been observed in concussion studies.162–166 These discrepancies may be due,
in part, to the considerable spatial heterogeneity in the
brain areas examined,167 as well as differences in the postinjury interval. FA may still have prognostic value, with
evidence suggesting that the direction and magnitude of
change correlates with clinical outcomes;166,168 however,
this idea awaits validation in both paediatric and adult
populations. FA might lack the necessary sensitivity to
fully appreciate changes in white matter tract integrity
following brain injury, and measures of diffusivity may
be more appropriate.169
The DTI field would benefit greatly from the development of normative data sets against which to gauge
observed changes. Pre-game versus post-game and
season-long studies of young athletes could employ
serial DTI imaging to establish normative data for a
particular individual, but the utility of the data when
pooled is unclear. The scarcity of normative paediatric
data severely limits the clinical usefulness of neuro
imaging techniques, including DTI. Studies of ‘returnto-baseline’ neuroimaging after paediatric concussion
are also needed, as they could greatly improve prediction of recovery. Although automation has increased
reproducibility, DTI measurements remain sensitive to
the hardware and software specifics, acquisition parameters and analysis software, which limit reproducibility,
standardization and comparison between centres and
across studies. Efforts to standardize DTI across imaging
centres are underway.170
MRI has been particularly successful in mapping
the brain’s ‘connectome’—the collection of structural
and functional neural connectivity networks and their
respective focal nodes—and for studying how concussion affects these networks. Focal or diffuse TBI can
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disrupt the brain’s functional connectivity, resulting in
dysfunction of multiple networks including the default
mode and salience networks, which have been implicated
in memory, emotion and mood.171 Network dysfunction
might have a stronger influence on recovery than does
lesion location, 171–173 but the long-term implications
for brain development and cognitive function remain
unclear.26,174 Further studies of network connectivity
dysfunction in children after concussion will be c ritical
to improve injury prognostication and management.
Radiotracers for PET imaging have the potential to
advance the diagnosis and treatment of concussion
and CTE, but their use in paediatric populations is
purely investigational at present. Three FDA-approved
radiolabelled imaging agents are currently available for
detecting brain amyloid in patients with suspected AD.175
In adults, some cases of concussion are associated with
acute Aβ pathology. PET scanning could enable paedi
atric patients to be monitored for the presence and
persistence of acute post-concussion amyloid, and to
determine whether scan positivity and negativity predict
different outcomes.176,177
Other PET imaging agents with potential utility in
paediatric populations include new tracers that bind
neurofibrillary tangles composed of tau. Early imaging
results with 18F‑T807, 18F‑T808 and 18F-THK5105 are
proving to be useful in confirming the presence of tau
opathy in various clinical situations, including AD.178–180
In a recent AD study, the magnitude of tau tracer signal
correlated positively with the stage of disease and severity
of cognitive impairment.180 A third tau PET tracer, 11CPBB3, has been tested in healthy individuals and patients
with AD, and may be able to detect non-AD conformations of tau.181 In addition, a recent report contains the
first description of tauopathy imaging in a living person
with suspected sports-associated CTE.177 Given the extent
of chronic tau pathology in concussion, repetitive subconcussive injury and CTE, tau tracers may be useful as
diagnostic and prognostic biomarkers (for example, to
distinguish CNI from CTE). Studies with these tracers in
adults with CTE are underway, but their use in paediatric
populations will depend on future research to determine
whether tau pathology is present in young patients after
TBI or concussion.
A PET tracer for the microglial cholesterol transporter
protein might be useful for imaging of neuroinflammation associated with TBI.182 New PET ligands to image
brain microglia, which are being developed with potential utility in neurodegenerative diseases, may also prove
useful in concussion and CTE management. Exploration
of these PET ligands in paediatric populations with concussion and TBI would be informative, but risk–benefit
analyses must be performed before embarking on studies
involving radiotracers in this age group. The ultimate
utility of any PET imaging agent will depend on its diagnostic and prognostic value as part of a multimodal panel
of biomarkers and neuroimaging techniques.
Noninvasive techniques such as transcranial magnetic
stimulation (TMS) have also uncovered changes in synaptic plasticity following TBI and concussion,183 particularly

in asymptomatic individuals.184–186 Several small TMS
studies of young athletes in their early 20s with a history
of concussion suggest imbalances in γ‑aminobutyric
acid and/or glutamate neurotransmission in the motor
cortex that are associated with deficits in synaptic longterm potentiation and depression.184,185,187,188 TMS has also
revealed that concussion-related impairments in synaptic
plasticity can impair aspects of motor learning,188 and that
these deficits are detectable decades after an individual’s
last concussion.189
Another crucial noninvasive tool for detecting neuro
chemical dysfunction associated with concussion is
proton magnetic resonance spectroscopy (MRS). Reports
specifically addressing the use of spectroscopy following
sports-related concussion suggest various abnormalities
consistent with neurochemical alterations.190 In younger
(high school) athletes, increased glutamate and glutamine
levels were detected by MRS at post-season versus preseason evaluation, even in players who had not experi
enced clinically significant concussion during the
season.191 Such findings suggest that even subconcussive
head impacts can result in the activation of glutamate
pathways, implying cellular injury or neuronal death,
despite the absence of symptoms. Levels of creatinine
and myoinositol (an organic osmolyte located in astrocytes192,193) were also significantly altered in a subset of the
participants in the aforementioned study.
In a rare longitudinal study utilizing MRS,194 individuals who sustained a single sports-related concussion
exhibited significantly reduced levels of N‑acetylaspartate
(NAA, a marker of neuronal and axonal health, integrity and functioning 195) in the brain 3 days after injury.
Levels were increased at 15 days post injury, and reverted
to control values at 30 days post injury. By contrast, parti
cipants who sustained a second concussion 10–13 days
after their initial concussion displayed a prolonged
reduction in NAA levels, which had not normalized even
45 days post injury. These results suggest that repeated
injury within a short time frame increases the likelihood
of protracted or incomplete recovery.
In addition to the acute and subacute alterations
detected by MRS, other studies of the long-term effects
of concussion have disclosed increased myoinositol
(associated with glial proliferation) and decreased cho
line (associated with membrane turnover 195) levels in the
medial temporal lobe in otherwise healthy former athletes who sustained their last concussion more than three
decades prior to testing.196 Another recent study examined a cohort of symptomatic retired National Football
League players, using an advanced MRS method called
correlated spectroscopy (COSY), which can measure
additional metabolites.197 The authors identified increased
choline and glutamate–glutamine levels (indicative of
diffuse axonal injury and excitotoxicity, respectively),
consistent with previous mTBI MRS studies, as well as
additional cerebral metabolites that were indicative of
neuroinflammatory changes. These metabolic changes
may provide insight into mechanisms of injury, such as
excitotoxicity and/or inflammation, which could underlie
the reported structural changes.
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Overall, the available data support the use of MRS
as a research tool to identify altered neurophysiology
and monitor recovery in adult athletes, even following
resolution of post-concussive symptoms. At present,
MRS-detected biochemical alterations may enhance our
understanding of the underlying pathophysiology, but do
not yet provide specific diagnostic information. Larger
cross-sectional, prospective and longitudinal studies are
needed to determine the sensitivity and prognostic value
of MRS within the field of sports-related concussion.190
Because the interpretation of MRS in the immature brain
requires certain developmental considerations, appropriate comparison samples will be needed for future work in
children. MRS techniques with greater spectral resolution,
including COSY, might provide additional biochemical
specificity.197 Other advances in spatial resolution, such as
3D chemical shift imaging, may also provide greater specificity by allowing the investigation of metabolic alterations
throughout the brain rather than in specific regions of
interest. Finally, MRS could have a role in measurement
of treatment effects, such as those induced by transcranial
direct current stimulation198 and TMS.199
Filling the gaps—neuroimaging biomarkers
■■ Better define the clinical relevance of changes in FA
and diffusivity DTI measures after concussion
■■ Develop normative DTI data sets for paediatric
concussion populations
■■ Describe how focal and diffuse brain injuries affect
connectivity network function in developing brains.
How do these changes influence symptomatic and
functional recovery from concussion in children?
■■ Investigate amyloid, tau and inflammatory PET
imaging in appropriate clinical populations
■■ Encourage the use of standardized imaging acquisition protocols across centres conducting concussion
research
■■ Improve our understanding of ‘return-to-baseline’
recovery mechanisms and trajectories
■■ Explore the research utility of MRS in paediatric
patients with concussion

Injury surveillance and data sharing
Surveillance infrastructure
The mechanisms and surveillance infrastructure for
sports-related injury measurement, reporting, tracking
and data sharing are insufficient for current needs and
objectives. Concussion research and clinical efforts are
hindered by a lack of concussion data across sports and
playing levels. A 2014 Institute of Medicine report identified only three national sports injury surveillance systems:
the National Electronic Injury Surveillance System—All
Injury Program (NEISS-AIP), the National Collegiate
Athletic Association Injury Surveillance System (NCAA
ISS), and the High School Reporting Injury Online
(RIO™).1 These systems can be supplemented with clinical data (for example, from emergency departments, hospitalized inpatients and sports clinics), but these data are
biased toward more-severe injuries and patients of higher
socioeconomic status. Indeed, schools in rural areas or

communities with lower socioeconomic status often
have limited access to sports medicine care professionals
and facilities.
Several emerging programmes may improve surveillance. Regional efforts such as Clinical Outcomes
Research Education for Athletic Trainers (CORE-AT)
and national efforts such as the National Athletic Trainers’
Association National Athletic Treatment, Injury and
Outcomes Network (NATA NATION™) attempt to integrate injury tracking with treatment and outcomes data
at the high school and collegiate levels. However, none of
these systems specifically capture injuries to younger athletes, those participating in non-school sponsored sports,
or those at schools without athletic trainers. Sports injury
databases also rarely account for demographic factors
including socioeconomic status, race or ethnicity, and
health-care coverage.
Currently, no effective mechanisms exist to consistently
and inexpensively link various surveillance data sets, or
to follow up individual athletes across sports, tracking
systems or the age continuum. There is a considerable need
for a system that tracks individual athletes through their
playing careers and beyond. Each individual should be
tracked for several decades to establish if, when and how
a given burden of TBI evolves into CTE, and to assess all
the possible negative health outcomes associated with concussion. Such a system would also provide more-accurate
descriptions of concussion history and exposure to risk
factors, and could capture both short-term and long-term
outcomes, including measures of physical and mental
health, academic and career success, quality of life and
social connectivity, and evolving socioeconomic status.
Such efforts are challenged by a variety of issues, including a lack of mandatory reporting of concussion at any
level. Mandatory concussion reporting, funding for surveillance efforts, and provision of training to data reporters (for example, coaches and athletic trainers) would
greatly improve epidemiological research. However,
mandatory reporting will not provide meaningful results
without validated, consensus definitions for concussions,
and development of a universal data repository and a
global unique identifier (GUID) system. Data sets from
standardized surveillance efforts could then be linked,
thereby improving data sharing for research and clinical
care. Coupling of surveillance data with standardized collection, storage and curation infrastructures for biobanking of tissue and fluid samples could dramatically improve
injury and outcomes research.200 These efforts might be
catalyzed by funding from public–private partnerships,
and made actionable by setting realistic short-term and
long-term goals to create a multi-year plan. However, in
the USA at least, such efforts are currently hampered by
misunderstanding of Health Insurance Portability and
Accountability Act (HIPAA) regulations and general
concerns for athlete confidentiality.
Computerized neurocognitive testing
Wider use of computerized neurocognitive testing
(CNT) for athletes could improve concussion surveillance, as well as diagnosis and management. However,
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several important challenges must be overcome before
CNT becomes routine. These challenges include a lack of
standardized administration protocols, the potential for
technological errors arising from different computer hardware, limits in the types of cognitive functions assessed,
and a lack of qualified test administrators and data interpreters.201 Despite these shortcomings, however, CNT is
already used by approximately 40% of US high schools
that employ athletic trainers.202 Though not affordable
for all schools, CNT could enhance ground-level data
collection and aid risk-exposure estimation and postconcussion recovery tracking, as well as increasing the
quality of data reported to sports injury surveillance networks. CNT may be also useful in evaluating and tracking
post-concussion cognitive improvement or decline, and
could have utility in predicting outcomes.203,204 Whether
CNT data collected in the school setting will reach the
validation and reproducibility standards achieved by CNT
conducted by a clinical research team remains to be seen.
Importantly, CNT needs standardization and guidelines
for determining ‘return to play’ and ‘return to learn’ for
athletes who show recovery in one domain but are still
symptomatic in others. More research is required on
the utility of CNT, both in the clinic and for concussion
surveillance and management of youth athletes.
Filling the gaps—data collection and sharing
■■ Institute mandatory, standardized concussion
reporting at all levels of youth sports
■■ Develop mechanisms to link existing surveillance
data sets and improve capacity for long-term t racking
across sport, school and age
■■ Develop a GUID system that can track players across
data collection systems, yet is inexpensive, feasible
and acceptable to those with HIPAA and/or athlete
confidentiality concerns
■■ Expand demographic data collection in existing surveillance systems to include factors such as race and
ethnicity, and socioeconomic status
■■ Increase use of validated concussion assessment tools
in middle and high school athletic programmes
■■ Increase use of CNT as a research tool

Accelerating research progress
Short-term studies
In several critical areas, incomplete knowledge hampers
meaningful advances in the field of paediatric concussion.
At the molecular and cellular levels, research that focuses
on axonal damage after concussion and repetitive subconcussive injury is urgently needed to elucidate changes
in axonal trafficking and repair, and to better define the
role of transient Aβ accumulation as a potential driver
of downstream and/or future pathology. Concussion
researchers may need to identify more-suitable animal
models to study molecular pathology, including tau and
its contribution to post-concussion and CTE pathologies,
as the structure and organization of the brain differs dramatically in rodents and humans. Without a clearer understanding of how TBI changes the young, still-developing
brain, and what pathological events happen in the weeks,

months and years following injury, we are left to speculate
about the underlying biological bases of such changes.
Head impact data collection and risk assessment in
youth sports might be improved through use of sensor
technologies that record linear and rotational forces.
Such commercially available devices, if validated, could
determine levels of cumulative head impact forces during
games and across seasons of play, and the findings could
be linked to neuroimaging data and functional outcome
assessments. Combined with ‘hit-count’ metrics, sensor
data may improve knowledge of short-term and long-term
neuropsychological outcomes of repetitive subconcussive
impacts. Our knowledge of CTE might be improved by
understanding baseline rates in the general population,
in injured athletes, among uninjured athletes matched
by sport and playing positions, and in ‘control’ athletes
in low-risk sports. Improved knowledge of risk exposures
could lead to prevention efforts, including practice and
competition rule changes.

Longitudinal studies
A decades-long, prospective, longitudinal study, following youth athletes through their sporting careers and
beyond, would provide more-definitive knowledge of
cumulative head impacts and risks of long-term neuro
psychological dysfunction and dementia. Such a study
is underway in NCAA alumni, who were first studied in
2003 and were re-assessed in 2013.29,205 Studies in other
populations, especially if NIH-funded, would probably begin with a 5‑year study that could be renewed in
further 5‑year increments. Public–private partnerships
are likely to be required to secure enough funding to
involve multiple study centres. The NCAA has provided
partial sponsorship for the 10-year re-assessment of over
100 athletes, but further funding from the NIH, the US
Department of Defense (DoD), and private philanthropic
sources will be required to extend the range of assessment from neuropsychology, through MRI, to molecular
imaging for amyloid, tau and/or inflammation.
Ideally, the longitudinal study design should combine
epidemiological and interventional trial methodologies and utilize multiple control groups, including noncontact athletes and uninjured impact sport athletes. A
longitudinal study would also shed light on the role of
cognitive reserve. A precedent for such studies has been
established by the late-life dementia research community, using NIH funds and public–private partnerships
involving pharmaceutical companies and foundations.
For such studies to be successful, additional surveillance
systems and data repositories must first be established.
Efforts would be accelerated if athletes participating in
impact sports had universal access to athletic trainers,
who could act as reliable data reporters while promoting
safety and providing basic care. In addition, any longitudinal studies must include postmortem analyses to better
understand the influence of childhood and young-adult
concussions on the development of neurodegenerative
pathology and dementia in later life.
‘Return-to-play’ guidelines are currently hampered by
a lack of rigorous epidemiological evidence, and could be
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greatly improved by long-term safety data from longitudinal studies.206 Longitudinal research could also include
studies to determine whether those athletes who fail to
follow guidelines experience any negative health effects,
such as lingering symptoms or altered risk of incurring
a second concussion.
The infrastructure for a long-term prospective study
might be created through the formation of a research
consortium modelled after the Alzheimer’s Disease
Neuroimaging Initiative (ADNI). ADNI has set standards for data collection, dissemination agreements, testing
methodologies, and biomarker collection and analysis.
A version of ADNI currently underway with participation of the DoD (ADNI-DoD) is focused on blast-related
TBI research in military populations.207 In May 2014, in
addition to the NCAA Concussion Study, the NCAA
and the DoD announced the launch of the largest prospective sports-related concussion study to date, which
will monitor approximately 37,000 NCAA athletes over
3 years. One can envision how this study’s infrastructure
may eventually be extended to study younger athletes
over an extended l ongitudinal range.

Drug repurposing and drug discovery
Many gaps remain in our knowledge of the biology of
TBI, which limit our ability to develop effective drugs.
These gaps must be filled if we are to tackle the underlying disease pathology and move beyond treating the
symptoms. However, much can be accomplished while
research into fundamental TBI biology continues.
Drug repurposing involves testing of existing FDAapproved drugs for new indications, and can reduce
expense and shorten the path for drug approval. Current
repurposing trials include methylphenidate for pain
and mental fatigue,208 the dopamine receptor agonist
bromocriptine for working memory,209 and the antidepressant sertraline for mood and anxiety, the most
frequent neuropsychological complications that influence long-term outcomes after concussion.210 Larger
randomized clinical trials should be conducted before
these drugs can be introduced into clinical practice for
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these new indications. In addition, the recent failure
of the PROTECT phase III trial of progesterone to
improve outcomes after acute TBI 211 may serve as
a reminder of the need for more research to better
understand the fundamental biology underlying TBI.
Although many drug repurposing efforts are designed
primarily to address concussion symptoms, the drugs
may also influence injury pathology and progression.
Research on established drugs can also lead to new drug
discovery efforts and, potentially, new preventive or
management therapeutics.
New drugs are urgently needed for TBI and concussions
that do not resolve. Drug discovery efforts in the areas of
neuroprotection and anti-inflammation are especially
relevant because of their potential cross-applicability to
neurodegenerative diseases such as AD. Similarly, drugs
currently in development for other neurodegenerative
diseases might be repositioned for testing in patients with
TBI or nonresolving concussion symptoms.

Conclusions

As is often the case in medical research, recent advances
in concussion research raise as many questions as they
answer. Evidence exists for long-term neuropsychological dysfunction and later-life dementia after concussions
or repetitive subconcussive head impacts, and more
work is needed to better understand the implications
and outcomes of youth participation in impact sports.
As outlined in this Expert Consensus Document, there is
a path forward, but achieving the goals outlined here will
require public and private sector cooperation. While recommendations can be improved with increased knowledge, the available evidence can still inform individual
decision-making when considering youth sport participation, as well as practice policies and competition rules.
With an ageing population and a looming epidemic of
dementia, we must learn more about potential early-life
risk factors, including sports-related concussion. The
choices made by parents, coaches, school boards and
children will be better informed when the critical gaps
in scientific knowledge of concussion are filled.
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